863 / 1138
CONCLUSIONS
•
Initial results are promising in terms of
−
Biochemical response / control
−
GI Toxicity
•
Increased rates of GU toxicity
•
Un-answered questions
−
Clinical patient selection factors : P-Vol, IPSS, …
−
OAR tolerance doses
−
Prophylactic / premedication: tamsulosin, steroids …
−
Role in intermediate and high risk patients
−
Toxicity and biochemical control with sufficient FU
Should be practiced within prospective protocolls
38
ESTRO SBRT Course 2014 - Emerging SBRT indications
SBRT for prostate cancer